These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38582643)

  • 1. Front-line Platinum Continues To Have a Role in Advanced Bladder Cancer.
    Vogl UM; Testi I; De Santis M
    Eur Urol Focus; 2024 Mar; 10(2):217-218. PubMed ID: 38582643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Paradigm shift in systemic therapy for metastatic urothelial carcinoma-antibody-drug conjugates (ADCs) and fibroblast growth factor receptor (FGFR) inhibitors].
    Casuscelli J; von Amsberg G; Retz M
    Urologie; 2024 Oct; 63(10):1002-1010. PubMed ID: 39235511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Powles T; Valderrama BP; Gupta S; Bedke J; Kikuchi E; Hoffman-Censits J; Iyer G; Vulsteke C; Park SH; Shin SJ; Castellano D; Fornarini G; Li JR; Gümüş M; Mar N; Loriot Y; Fléchon A; Duran I; Drakaki A; Narayanan S; Yu X; Gorla S; Homet Moreno B; van der Heijden MS;
    N Engl J Med; 2024 Mar; 390(10):875-888. PubMed ID: 38446675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine with cisplatin and nivolumab: Redefining standard of care for first-line metastatic urothelial carcinoma?
    Mathew Thomas V; Grivas P; Agarwal N
    Med; 2024 Feb; 5(2):109-111. PubMed ID: 38340704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
    Bellmunt J; Nadal R
    Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria.
    Apolo AB; Bellmunt J; Cordes L; Gupta S; Powles T; Rosenberg JE; Van Der Heijden MS
    ESMO Open; 2024 Sep; 9(9):103725. PubMed ID: 39236601
    [No Abstract]   [Full Text] [Related]  

  • 7. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
    Zhu X; Koshkin VS
    Med; 2024 Feb; 5(2):106-108. PubMed ID: 38128535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
    Benjamin DJ; Rezazadeh Kalebasty A; Prasad V
    Eur Urol Oncol; 2024 Jun; 7(3):313-315. PubMed ID: 38485615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma.
    Maguire WF; Lee D; Weinstock C; Gao X; Bulik CC; Agrawal S; Chang E; Hamed SS; Bloomquist EW; Tang S; Pazdur R; Kluetz PG; Amiri-Kordestani L; Suzman DL
    Clin Cancer Res; 2024 May; 30(10):2011-2016. PubMed ID: 38441576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new era for bladder cancer: Enfortumab vedotin and pembrolizumab milestone approval.
    Zameer U; Shaikh W
    Tumori; 2024 Aug; 110(4):295-296. PubMed ID: 38142292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
    Hoimes CJ; Flaig TW; Milowsky MI; Friedlander TW; Bilen MA; Gupta S; Srinivas S; Merchan JR; McKay RR; Petrylak DP; Sasse C; Moreno BH; Yu Y; Carret AS; Rosenberg JE
    Future Oncol; 2024 Mar; 20(7):351-360. PubMed ID: 37994649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.
    Merseburger AS; Apolo AB; Chowdhury S; Hahn NM; Galsky MD; Milowsky MI; Petrylak D; Powles T; Quinn DI; Rosenberg JE; Siefker-Radtke A; Sonpavde G; Sternberg CN
    World J Urol; 2019 Jan; 37(1):95-105. PubMed ID: 30238401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab plus enfortumab vedotin in urothelial cancer.
    Santoni M; Takeshita H; Massari F; Bamias A; Cerbone L; Fiala O; Mollica V; Buti S; Santoni A; Bellmunt J
    Nat Rev Urol; 2024 Jul; 21(7):387-388. PubMed ID: 38267716
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune checkpoint inhibitors for urothelial carcinoma.
    Kim HS; Seo HK
    Investig Clin Urol; 2018 Sep; 59(5):285-296. PubMed ID: 30182073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
    Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
    Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Catalano M; Santoni M; Roviello G
    Eur Urol; 2024 Sep; 86(3):283. PubMed ID: 38744633
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Klümper N; Vera-Badillo FE; Eckstein M; Hadaschik B; Grünwald V
    Eur Urol; 2024 Sep; 86(3):280-281. PubMed ID: 38599990
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Chen DC; AlSaffar H; Graefen H; Perera S; Mazzone E; Perera ML; Lawrentschuk N; Murphy DG
    Eur Urol; 2024 Sep; 86(3):282-283. PubMed ID: 38631993
    [No Abstract]   [Full Text] [Related]  

  • 19. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
    Powles T; Bellmunt J; Comperat E; De Santis M; Huddart R; Loriot Y; Necchi A; Valderrama BP; Ravaud A; Shariat SF; Szabados B; van der Heijden MS; Gillessen S;
    Ann Oncol; 2024 Jun; 35(6):485-490. PubMed ID: 38490358
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
    Brown JR; Koshkin VS
    Eur Urol Focus; 2024 Mar; 10(2):231-233. PubMed ID: 38797658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.